Jeff R. Infante, MD, director, Drug Development Program, Sarah Cannon Research Institute, discusses a phase I study of the novel immunotherapy agent AM0010 and its early promise in patients with renal cell carcinoma.
Jeffrey R. Infante, MD
Advertisement
Articles by Jeffrey R. Infante, MD
Jeffrey R. Infante, MD, director, Drug Development Program, Sarah Cannon Research Institute, discusses the potential impact avelumab could have on the treatment of patients with ovarian cancer.
Dr. Jeffrey Infante from Sarah Cannon Research Institute on the Next Step in Melanoma Research
Dr. Infante from Sarah Cannon Research Institute on the Future of BRAF Inhibitors in Melanoma
Dr. Infante from Sarah Cannon Research Institute Talks About BRAF Mutation Testing
Advertisement
Latest Updated Articles
Dr. Infante on the Next Step in Melanoma ResearchJune 23rd 2011
Dr. Infante on Avelumab's Potential in Ovarian CancerJuly 22nd 2015
Dr. Infante on AM0010 in Patients With RCCMay 11th 2016
Dr. Infante Talks About BRAF Mutation TestingJune 7th 2011
Advertisement
Advertisement
Trending on OncLive
1
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
2
TALAPRO-3 Shows Talazoparib Plus Enzalutamide Improves rPFS in HRR-Altered mCSPC
3
Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis
4
Dr Eads on Early Data for CDH17-Directed CAR T-Cell Therapy in R/R GI Cancers
5